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Chemically induced skin carcinomas in mice are a paradigm for
epithelial neoplasia, where oncogenic ras mutations precede p53
and INK4ayARF mutations during the progression toward malig-
nancy. To explore the biological basis for these genetic interac-
tions, we studied cellular responses to oncogenic ras in primary
murine keratinocytes. In wild-type keratinocytes, ras induced a
cell-cycle arrest that displayed some features of terminal differen-
tiation and was accompanied by increased expression of the
p19ARF, p16INK4a, and p53 tumor suppressors. In ARF-null keratin-
ocytes, ras was unable to promote cell-cycle arrest, induce differ-
entiation markers, or properly activate p53. Although oncogenic
ras produced a substantial increase in both nucleolar and nucleo-
plasmic p19ARF, Mdm2 did not relocalize to the nucleolus or to
nuclear bodies but remained distributed throughout the nucleo-
plasm. This result suggests that p19ARF can activate p53 without
overtly affecting Mdm2 subcellular localization. Nevertheless, like
p53-null keratinocytes, ARF-null keratinocytes were transformed
by oncogenic ras and rapidly formed carcinomas in vivo. Thus,
oncogenic ras can activate the ARF-p53 program to suppress
epithelial cell transformation. Disruption of this program may be
important during skin carcinogenesis and the development of
other carcinomas.
Normal cells possess natural defense mechanisms thatcounter uncontrolled mitogenic signaling, and these safe-
guards may be eliminated by mutation during multistage carci-
nogenesis (1). One such safeguard is illustrated by the trans-
forming interactions between oncogenic ras and various tumor
suppressor genes in primary fibroblasts. The ras family of
proto-oncogenes are small GTPases that, when activated by
mutation, constitutively transmit growth promoting signals via
the mitogen-activated protein kinase (MAPK) cascade and
other pathways (2). Oncogenic ras readily transforms immortal
rodent cell lines; however, it is unable to transform primary cells
because it induces a premature senescence program involving
tumor suppressors such as p53, p16INK4a, p19ARF, p15INK4b, and
the promyelocytic leukemia gene product (PML; refs. 3–7).
Importantly, mutations that disable the arrest program cooper-
ate with ras in transformation (5, 8–10). Given the high fre-
quency of ras, p53, and INK4ayARF mutations in human cancers
(11), this safeguard may be an important tumor suppressor
mechanism.
The INK4ayARF locus is a critical sensor of hyperproliferative
signals produced by ras and other oncogenes (12). This locus
encodes the two structurally unrelated tumor suppressors
p16INK4a and p19ARF (13, 14). p16 INK4a, an inhibitor to cyclin
D-dependent kinase, regulates the retinoblastoma (Rb) protein
to block the G1-S transition (15). In contrast, p19ARF can activate
p53 by interfering with the p53 antagonist Mdm2 (16–19),
leading to cell-cycle arrest or apoptosis depending on context
(12). Both p16INK4a and p19ARF accumulate during the serial
passaging of cells in culture (20–22), and can be induced acutely
by expression of mitogenic oncogenes (4, 21–23). Oncogenic ras
induces p16INK4a and p19ARF through the MAPK cascade,
suggesting that the process is directly coupled to the pro-
mitogenic activity of oncogenic ras (9). Both p16INK4a and
p19ARF may contribute to premature senescence in human cells,
whereas p19ARF dominates the program in rodent cells (4, 9, 22).
Thus, primary fibroblasts derived from ARF2/2 mice fail to
arrest in response to oncogenic ras and are transformed by ras
alone (4, 24).
Fail-safe mechanisms involving ras, the INK4ayARF locus, and
p53 have been described in fibroblasts, but much less is known
about the processes in epithelial cells—the normal precursor to
most adult cancers. Perhaps the most well characterized model
of epithelial neoplasia involves chemically induced skin carci-
nogenesis in mice (25). In this paradigm, animals are treated with
a carcinogen, 7,12-dimethylbenz[a]anthracene (DMBA), and a
tumor promoter, phorbol 12-tetradecanoate 13-acetate (TPA).
DMBA treatment produces ras mutations and, with continued
application of TPA, benign papillomas. Progression to squamous
cell carcinomas is a rare event that requires additional mutations,
including inactivation of p53 and the INK4ayARF locus (25).
Although the biological basis for these genetic interactions is
unknown, they can be recapitulated by using transgenic and
knockout mice. For example, loss of p53 promotes the progres-
sion, but not initiation, of chemically induced carcinomas (26).
The epidermal keratinocyte is the normal cell precursor to
squamous cell carcinoma of the skin. In normal skin, keratino-
cytes undergo a continuous process of proliferation and differ-
entiation as a self-renewal program (27). This differentiation
program is characterized by an irreversible cell-cycle exit and the
induction of well-established differentiation markers (27). Pri-
mary murine keratinocytes proliferate for several passages in
culture, but undergo a normal differentiation program after
calcium addition (28). Notably, oncogenic ras cooperates with
p53 loss to oncogenically transform primary keratinocytes (29),
demonstrating that this simplified system recapitulates the ge-
netic interactions involved in tumor progression in vivo. In this
study, we examined cellular responses to ectopic expression of
oncogenic ras in primary epidermal keratinocytes. Our results
highlight the role of ARF-p53 pathway during epithelial cell
transformation, and suggest a biological basis for genetic inter-
actions involved in chemically induced skin carcinogenesis.
Materials and Methods
Cell Culture. Primary epidermal keratinocytes populations were
prepared from newborn mice (2 days old) that are wild-type,
ARF-null (24), and p53-null (30) by using a previously published
protocol (31) with minor modifications. Briefly, mice skins were
floated, dermis down, in 0.05% trypsiny0.5 mM EDTA at 4°C
overnight. Afterward, skin pieces were placed with the dermis-
side up, and the dermis was peeled back with a forceps.
Keratinocytes were isolated by trypsinizing the tissues for an
additional 15 min at 37°C. Cells were collected, washed in PBS
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containing 0.5% FBS and were resuspended in serum-free
keratinocyte medium with supplements [recombinant epidermal
growth factorybovine pituitary extract (GIBCO)y50 units/ml
penicillin Gy25 mg/ml streptomycin sulfatey0.3 mM Ca21]. Cells
were plated at 0.5 mouse equivalents per 60-mm Petri dish, after
which the medium was changed and the calcium concentration
was reduced to 0.05 mM. Keratinocytes were subcultured once
(1:3 dilution) for subsequent experiments.
Retroviral Gene Transfer. Helpervirus-free retroviruses expressing
H-rasV12 [pBabe-Puro-ras (3)] or an empty vector were pro-
duced by transient transfection of the Phoenix ecotropic pack-
aging line (G. Nolan, Stanford University) as previously de-
scribed (3). Filtered supernatant supplemented with 4 mgyml
polybrene was used to infect freshly isolated mouse skin kera-
tinocytes within 24 to 48 hr postplating (3). Meanwhile, the
packaging cells were replenished with keratinocyte medium
containing 10% Chelex-treated FBS (Chelex-100, Sigma), and
the virus-containing supernatant was collected every 6 hr for two
additional infections. Twelve hours after the last infection, the
cells were selected in 1.5 mgyml puromycin for 48 h.
Measurement of Cell Proliferation. Mouse skin keratinocytes were
plated onto LAB-TEK Chamber Slides (Nalge Nunc) and were
subsequently labeled with BrdU (100 mgyml, Sigma) and
5-fluoro-29-deoxyuridine (FdU, 10 mgyml, Sigma) for 12 h. Cells
were fixed in 4% paraformaldehydeyPBS for 15 min. After
fixation, cells were permeabilized, denatured, and labeled with
BrdU as previously described (9). BrdU incorporation was
measured by immunofluorescence by using an FITC-conjugated
anti-BrdU antibody (1:200, Amersham Pharmacia), and DNA
was stained by 49,6-diamidino-2-phenylindole (DAPI; 1 mgyml).
DNA content analysis by using propidium iodide and flow
cytometry was carried out as described (9).
Immunoblotting. Western blot analysis was carried out on whole
cell lysates as previously described by using enhanced chemilu-
minescence (ECL; Amersham) detection (9). Typically, 20 mg of
proteins from each sample were loaded and separated by
SDSyPAGE and transferred to Immobilon-P membranes (Mil-
lipore). Blots were probed with the following antibodies: anti-
p53 (CM5, 1:2000, Novocastra, Newcastle, U.K.), anti-p19ARF
(1:500, Novus Biologicals, Littleton, CO), anti-p16 (M156, 1:500,
Santa Cruz Biotechnology), anti-p21 (C-19, 1:500, Santa Cruz
Biotechnology), anti-mouse keratin 5 (K5, 1:1000, BAbCO,
Richmond, CA), anti-Ras (OP23, 1:200, Oncogene), anti-
involucrin (1:1000, BAbCO), anti-filaggrin (1:2000, BAbCO).
Immunostaining. Cells were fixed in 4% paraformaldehyde fol-
lowed by permeabilization in 0.2% Triton X-100y0.5% normal
goat serumyPBS. Cells were subsequently incubated for 1 hr at
room temperature with the following antibodies, respectively:
CM5 (anti-p53, Novocastra, 1:200), anti-p19ARF (Novus Biologi-
cals, 1:100), anti-Mdm2 (2A10 or 4B11, generously provided by
Dr. A. Levine, The Rockefeller University, 1:50), anti-K5
(1:1000, BAbCO), anti-involucrin (1:600, BAbCO), and anti-
fibrillarin (1:50, Sigma). Alexa Fluor Conjugates (Molecular
Probes) were used as the secondary antibodies, and DNA was
visualized by using DAPI. Confocal images were obtained by
using a Zeiss LSM 510 confocal laser scanning microscope.
Tumorigenicity Assays. Two days after selection, retrovirally trans-
duced cells were collected, and 5 3 105 cells were injected s.c.
into nude mice (two sitesymouse). Tumor growth was monitored
every 3 days by palpation at the sites of injection. The length (L)
and width (W) were measured by using a caliper, and the volume
of tumor formed was determined by using the formula V 5 (L 3
W2y2. After 3 weeks, each tumor was dissected, weighed, and
fixed in formalin for staining with hematoxylin and eosin.
Results
Oncogenic ras Induces Cell Cycle Arrest in Primary Murine Keratino-
cytes. Primary epidermal keratinocytes were isolated from new-
born mice and cultured in serum-free medium by using condi-
tions that do not support fibroblast growth. By using this
procedure, pure keratinocyte populations were obtained, as
judged by their polygonal morphology and immunoreactivity
with a K5-specific antibody (Fig. 1). Twenty-four hours later,
keratinocytes were infected with high-titer retroviruses coex-
pressing oncogenic ras (H-rasV12) with a puromycin resistance
gene to isolate cells in which the virus was stably transduced. A
vector expressing the puromycin resistance gene alone was used
as a control. This procedure resulted in the infection of .30%
of keratinocytes as measured in parallel infections by using a
green fluorescence protein (GFP)-encoding retrovirus (data not
shown). Infected cell populations were selected for 2 days in
puromycin, and then subcultured once for all subsequent anal-
yses. Hence, this procedure allowed us to examine the biological
consequences of ras expression in whole primary cell populations
without substantial growth or selection in culture.
Oncogenic ras expression produced marked changes to kera-
tinocyte morphology and proliferation that were not apparent in
populations expressing the control vector (Fig. 1 A; see also Figs.
2 and 3). By using a BrdU incorporation assay to determine the
percentage of cells synthesizing DNA, we observed a substantial
reduction in proliferation within 3 days of oncogenic ras trans-
duction (Fig. 1 A, quantified in 2B). The reduction of BrdU
incorporation was similar to that produced by the addition of
exogenous calcium (Figs. 1 A and 2B left), a stimulus that
initiates a normal program of terminal differentiation (28). Cells
arrested by both oncogenic ras and exogenous calcium displayed
a predominantly 2N DNA content, although ras-expressing cells
Fig. 1. Oncogenic ras arrests primary murine keratinocytes. Primary epider-
mal keratinocytes were infected with a control (Vector) or H-rasV12 (Ras)
retroviral vector. Alternatively, the cells were treated with medium containing
1.4 mM Ca21 (Ca21) to induce terminal differentiation. (A) Keratinocyte
populations were analyzed for K5 and involucrin expression by indirect im-
munofluorescence using antibodies directed against each protein. Cell pro-
liferation was measured by incubating cells with BrdU for 12 h, and identifying
BrdU-positive cells by immunofluorescence by using an antibody against BrdU.
Cells were counterstained with DAPI. Representative fields are shown. (B) Cell
cycle distribution of keratinocytes 48 hr after selection or calcium treatment.
Cells were fixed and stained with propidium iodide for the DNA content
analysis by using flow cytometry.
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retained more cells with a 4N content (Fig. 1B). The DNA
content profile of ras-expressing cells was similar to vector-
expressing controls (data not shown), with the only major
difference being a lack of BrdU incorporation in the ras-arrested
cells (Fig. 1 A). Similarly, cells arrested by both oncogenic ras and
exogenous calcium displayed features of terminal differentiation
(Fig. 1 A; see also Fig. 3). For example, immunofluorescence
experiments revealed that ’30% of the ras-expressing keratin-
ocytes were positive for involucrin (Fig. 1 A), a major protein
precursor of the epidermal cornified envelope and a differen-
tiation marker (32). However, calcium-induced differentiation
was more robust, because virtually 100% of these cells were
involucrin-positive. Therefore, oncogenic ras can induce a cell-
cycle arrest in epidermal keratinocytes that has some features of
terminal differentiation.
p19ARF Is Required for ras-Induced Arrest. In fibroblasts, ras-induced
cell-cycle arrest is accompanied by up-regulation of several
tumor suppressors, including p53, p16INK4a, p19ARF, p15INK4b,
and promyelocytic leukemia gene product (PML), and each of
these proteins contributes to the arrest program in some settings
(3–7). To determine whether some of these proteins are altered
during ras-induced arrest in keratinocytes, we performed a series
of Western blots on total cell extracts from ras-expressing
keratinocytes and their normal (vector) counterparts. Expres-
sion of oncogenic ras produced substantial increases in p19ARF,
p53, the p53 transcriptional target p21, and p16 within 4 days of
gene transfer (Fig. 2 A, compare lanes 1 and 2). A similar
increase in p19ARF and p53 occurred in keratinocytes expressing
a constitutively activated MAPK kinase (MEK1Q56P), implying
that Ras induced p19ARF and p53 through deregulated MAPK
signaling (data not shown). Remarkably, p16INK4a expression
was extremely high in ARF-null keratinocytes (Fig. 2 A, compare
lanes 1 and 3), suggesting that ARF-null cells are resistant to p16
inhibition, or that the expressed p16 is not an effective cyclin-
dependent kinase (cdk) inhibitor.
In murine fibroblasts, ARF and p53 are required for ras-
induced arrest, because disruption of either gene circumvents
arrest and allows uncontrolled proliferation (3, 4). To determine
whether the ARF-p53 pathway is operative in keratinocytes, we
tested whether oncogenic ras could induce p53 and promote
cell-cycle arrest in keratinocytes derived from ARF-null
(ARF2/2) mice. Oncogenic ras did not induce p53 in ARF2/2
keratinocytes, and the induction of p21 was substantially reduced
compared with wild-type cells (Fig. 2 A, compare lanes 2 and 4).
Furthermore, ARF2/2 cells did not arrest in response to onco-
genic ras, and incorporated as much BrdU as controls (Fig. 2B).
It seems unlikely that the failure of ARF2/2 cells to arrest is due
to rare secondary mutations that exist in these cells, because a
large percentage of the initial populations were infected and
then analyzed within days. Similar results were observed in
p532/2 keratinocytes (data not shown). Thus, disruption of ARF
prevents ras-induced arrest in murine keratinocytes, apparently
because ras is unable to efficiently activate p53.
Consistent with their failure to arrest, ARF2/2 cells express-
ing oncogenic ras did not acquire features of terminal differ-
entiation. Hence, these cells did not acquire the enlarged and
f lat morphology characteristic of ras-arrested controls (Fig.
3A). Similarly, as shown by immunoblotting of SDSy
polyacrylamide gels, these cells did not induce involucrin or
filaggrin, another differentiation-associated marker (Fig. 3B,
compare lanes 2 and 4). During keratinocyte differentiation,
involucrin and filaggrin are processed and expressed in mul-
tiple electrophoretically distinct forms (33, 34). Although
these expression patterns were induced by ras in normal
keratinocytes, they were not detected in ARF2/2 cells. Para-
doxically, ARF2/2 cells reproducibly displayed substantially
higher levels of involucrin than wild-type cells, although the
significance of this observations is unknown (Fig. 3B, compare
lanes 1 and 3). Together, these data indicate that the induction
of differentiation-associated markers by oncogenic ras is not a
direct consequence of Ras signaling but, rather, accompanies
cell-cycle arrest.
Fig. 2. p19ARF is required for ras-induced arrest of keratinocytes. Primary skin
keratinocytes were isolated from wild-type (WT) or ARF-null (ARF2/2) mice.
Cell populations were transduced with a control vector (V) or oncogenic ras
(R), or were with 1.4 mM Ca21 for 48 h. (A) Western blot analysis of whole cell
lysates by using antibodies against p19ARF, p53, p21, p16INK4a, Ras, and K5.
p53-null (p532/2) mouse embryonic fibroblasts (MEF) were used as a control.
(B) The cell populations described above were labeled with BrdU and fixed,
and the percentage of BrdU-positive cells was determined by immunofluo-
rescence by using an FITC-conjugated anti-BrdU antibody. The percentage of
BrdU-positive cells was determined by counting the BrdU-positive cells among
at least 200 cells from each sample. The results represent the mean 6 SD from
three experiments.
Fig. 3. p19ARF is not required for terminal differentiation. (A) Morphological
appearance of the cell populations described in Fig. 2. Photographs were
taken 48 hr after selection for virus-infected cells, or 48 hr after calcium
treatment. (B) Expression of differentiation-associated markers, as shown by
using immunoblotting with antibodies directed against involucrin and filag-
grin. Extracts from MEFs were used for comparison. V, vector; R, H-rasV12. (C)
Expression of differentiation-associated markers in wild-type (WT) and ARF2/2
keratinocytes treated with exogenous calcium. Cell extracts were prepared at
the indicated times posttreatment, and analyzed by immunoblotting using
antibodies directed against involucrin or filaggrin.








p19ARF Is Not Required for Terminal Differentiation Induced by Cal-
cium. Although p19ARF was required for the induction of differ-
entiation markers by oncogenic ras, it was dispensable for
terminal differentiation initiated by exogenous calcium. Thus,
calcium did not induce p19ARF or other tumor suppressors in
primary keratinocytes (Fig. 2 A, compare lanes 2 and 6), and
ARF2/2 keratinocytes underwent an apparently normal differ-
entiation program (Fig. 2B). Specifically, ARF2/2 keratinocytes
were morphologically indistinguishable from controls after cal-
cium treatment (Fig. 3A), and achieved a similar increase in
involucrin and filaggrin as occurred in wild-type cells (Fig. 3C).
In fact, ARF2/2 cells treated with calcium appeared more fully
differentiated than normal cells expressing oncogenic ras; for
example, ARF2/2 cells treated with calcium became stratified
and formed tight junctions, whereas normal cells expressing
oncogenic ras did not (Fig. 3A; data not shown). Clearly, the
requirement for p19ARF during ras-induced arrest distinguishes
this process from normal differentiation.
p19ARF Does Not Overtly Alter Mdm2 Localization in ras-Arrested
Keratinocytes. Studies suggest that p19ARF activates p53 by in-
terfering with the ability of Mdm2 to antagonize p53 (35). In
some settings, p19ARF sequesters Mdm2 in the nucleolus, allow-
ing p53 to function unopposed in the nucleoplasm (36, 37). To
determine whether p19ARF alters Mdm2 localization in keratin-
ocytes, we examined the distribution of p19ARF, p53, and Mdm2
in control and ras-arrested keratinocytes by using antibodies
specific for each protein. Consistent with the immunoblotting
experiments, p19ARF and p53 were elevated in keratinocytes
expressing oncogenic ras compared with controls (Fig. 4 A and
B). As expected, a substantial amount of p19ARF localized to the
nucleolus, as demonstrated by its colocalization with the nucle-
olar marker, fibrillarin (Fig. 4 A and D). However, p19ARF also
was expressed in the nucleoplasm. Thus, the anti-p19ARF anti-
body produced clear nuclear staining that did not only colocalize
with fibrillarin (Fig. 4A) and was not present in ARF2/2 coun-
terparts (data not shown). Conversely, whereas p53 was ex-
pressed in the nucleoplasm, a substantial amount colocalized
with fibrillarin in the nucleolus (Fig. 4B). The immunofluores-
cence signal was specific for p53, because p532/2 cells expressing
oncogenic ras did not show nucleolar staining (data not shown).
Whether nucleolar p53 is functionally active remains to be
determined.
Although Mdm2 also accumulated in keratinocytes expressing
oncogenic ras, it did not localize to the nucleolus (Fig. 4C). In
fact, as indicated by using both standard immunofluorescence
and confocal microscopy, Mdm2 was distributed throughout the
nucleoplasm and excluded from the nucleolus (Fig. 4 C and D).
This nucleoplasmic staining was diffuse and did not localize to
nuclear bodies as has been described in some settings (17).
Although the experiments shown in Fig. 4 used the monoclonal
antibody 2A10 to detect Mdm2, we obtained identical results by
using antibody 4B11, which recognizes a distinct Mdm2 epitope
(data not shown). These results suggest that, at least in keratin-
ocytes, p19ARF does not activate p53 by sequestering Mdm2 in
the nucleolus. Indeed, the only compartment where p19ARF and
Mdm2 were coexpressed was in the nucleoplasm (Fig. 4D).
ARF-Null Keratinocytes Expressing Oncogenic ras Form Squamous Cell
Carcinomas. In murine fibroblasts and lymphoid cells, p19ARF
appears to activate p53 as part of a protective mechanism that
limits the transforming potential of mitogenic oncogenes (35).
In keratinocytes, p53 loss can facilitate ras-induced transfor-
mation, because p532/2 cells expressing oncogenic ras are
highly tumorigenic in immunocompromised mice (29). To
determine whether inactivation of ARF would also facilitate
keratinocyte transformation, we introduced oncogenic ras into
wild-type, ARF1/2, and ARF2/2 cells and tested the ability of
infected populations to form tumors when injected s.c. into
athymic ‘‘nude’’ mice. For comparison, we also tested p532/2
cells expressing oncogenic ras, as well as all cell populations
infected with the control retroviral vector. Infected cell pop-
ulations were selected with puromycin for 48 h, grown for 2
days in culture, and injected s.c. into nude mice. Tumor growth
was measured with time; at 3 weeks, tumors were removed,
weighed, and prepared for histological analysis.
Wild-type keratinocytes were not tumorigenic, irrespective of
whether they were controls or expressed oncogenic ras (Table 1).
In contrast, ARF2/2 keratinocytes expressing oncogenic ras gave
rise to rapidly growing tumors within 2 weeks of injection (Fig.
5; Table 1). p532/2 keratinocytes expressing oncogenic ras also
formed tumors, with a kinetics and frequency similar to ARF2/2
cells (Fig. 5A; Table 1). Neither ARF2/2 nor p532/2 keratino-
Fig. 4. p19ARF colocalizes with Mdm2 in the nucleoplasm of ras-arrested
keratinocytes. The subcellular localization of p19ARF (A), p53 (B), and Mdm2 (C)
was determined in keratinocyte populations expressing a vector control (Vec-
tor) or oncogenic ras (Ras) by immunofluorescence using antibodies specific
for each protein (see Materials and Methods). Each cell population was
costained with fibrillarin to mark the nucleolus, and counterstained with DAPI
to identify the nucleus. (D) ras-arrested keratinocytes were fixed, costained
with antibodies directed against p19ARF and Mdm2, and analyzed by confocal
microscopy. Note that the antibodies for p19ARF and p53 did not show a signal
in ARF2/2 and p532/2 cells (data not shown). All images were representative of
multiple fields and experiments.
Table 1. Tumorigenicity assay
Genotype* Tumorigenicity† Tumor weight, g‡ Histology
WT (Vector) 0y6 NA NA
WT (Ras) 0y6 NA NA
p532y2 (Vector) 0y2 NA NA
p532y2 (Ras) 4y4 0.27 6 0.15 SCC§
ARF2y2 (Vector) 0y5 NA NA
ARF2y2 (Ras) 5y5 0.9 6 0.5 SCC§
ARF1y2 (Ras) 3y3¶ 0.86 6 1.27 SCC¶
*Primary skin keratinocytes were derived from wild-type (WT), ARF-null
(ARF2y2), ARF heterozygous (ARF1y2), and p53-null (p532y2) mice and were
infected with control vector (Vector) or H-rasV12 (Ras).
†Tumorigenicity is defined as the ratio between the number of tumors arising
to the number of sites injected. Mice harboring tumors were examined for 3
weeks; mice that did not form tumors were examined for up to 3 months.
‡Tumor weights were measured 3 weeks after injection of cells.
§SCC, squamous cell carcinoma.
¶Allele-specific PCR revealed loss of the remaining wild-type ARF allele in all
tumors.
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cytes harboring the control vector formed tumors (Table 1).
Interestingly, ARF1/2 keratinocytes expressing oncogenic ras
also formed tumors (Table 1) and, as determined by using an
allele-specific PCR assay on tumor-derived DNA, those tumors
that formed lost the remaining wild-type ARF allele (data not
shown). These results imply that ARF is strongly selected against
during tumor outgrowth. In all cases, the tumors had features of
undifferentiated squamous cell carcinomas, and were anaplastic
with aberrant mitotic figures (Fig. 5B, Table 1). Taken together,
these data demonstrate that p19ARF suppresses ras-induced
transformation in epidermal keratinocytes, presumably by cou-
pling Ras mitogenic signaling to a p53 arrest program. As a
result, loss of ARF can cooperate with ras to promote squamous
cell carcinomas.
Discussion
In this study, we examined cellular responses to oncogenic ras
in primary epidermal keratinocytes—a well-characterized ep-
ithelial cell type that can be readily isolated from mice and is
the precursor for chemically induced skin carcinomas. As
previously reported for fibroblasts, expression of oncogenic ras
in keratinocytes induces p19ARF, p16INK4a, and p53, leading to
a cell-cycle arrest program. Similarly, an activated MEK1—a
downstream effector or Ras in the MAPK cascade—
recapitulates the effects of oncogenic ras in promoting both
fibroblast and keratinocyte arrest [(9); data not shown]. How-
ever, whereas the arrest program of fibroblasts resembles
cellular senescence, the process in keratinocytes is reminiscent
of terminal differentiation. In keratinocytes, loss of p19ARF
uncouples Ras signaling from p53 leading, ultimately, to
oncogenic transformation. Thus, both ARF2/2 and p532/2
keratinocytes expressing oncogenic ras rapidly form carcino-
mas on injection into nude mice. Previous reports introducing
v-H-ras (instead of the H-rasV12 used here) into keratinocytes
did not observe an obvious arrest, although v-H-ras does
transform p532/2 and p212/2 keratinocytes (29, 38, 39). Al-
though in this study we cannot rule out the possibility that
p19ARF also acts independently of p53 (40), our results provide
the first direct evidence that the ARF-p53 pathway can
suppress epithelial cell transformation.
That ras-arrested keratinocytes display features of terminally
differentiated skin raises the possibility that ras might transmit
differentiation signals during normal skin differentiation. Con-
sistent with this notion, Ras mediates a neuronal differentiation
program in PC12 cells after nerve growth factor (NGF) addition
(41), and MAPK activity is induced in keratinocytes after
addition of exogenous calcium (42). However, ras-induced arrest
in keratinocytes is distinct from terminal differentiation. First,
although ras-expressing keratinocytes induce certain differenti-
ation markers, the effect is not as robust as observed after
calcium addition, nor do the arrested cells acquire the morphol-
ogy of terminally differentiated keratinocytes. More impor-
tantly, the cell-cycle regulators that are activated in response to
oncogenic ras are not induced during terminal differentiation
(e.g., p19ARF, p53, p21, and p16INK4a), and mice lacking these
genes develop normal skin (8, 9, 24, 39, 43, 44). In fact, we show
that ARF2/2 keratinocytes are capable of terminal differentia-
tion although they fail to arrest in response to oncogenic ras.
Therefore, ras-induced arrest and differentiation achieve over-
lapping endpoints by using fundamentally different mechanisms.
This observation may reflect the unique purpose of each pro-
gram: whereas terminal differentiation of keratinocytes pro-
duces cellular specialization, ras-induced arrest of keratino-
cytes—like premature senescence in fibroblasts—counters
uncontrolled mitogenic signaling.
How does p19ARF activate p53 in ras-expressing keratino-
cytes? In normal cells, p53 protein level is tightly controlled by
Mdm2. Mdm2 antagonizes p53 function by preventing p53-
dependent transcription, by acting as an E3 ligase to facilitate
p53 degradation, and by promoting p53 nuclear export (35).
p19ARF physically associates with Mdm2, which presumably
uncouples Mdm2 from p53 (16–19). How this uncoupling
occurs may depend on context, but most studies suggest that
p19ARF alters Mdm2 compartmentalization. For example,
some studies demonstrate that p19ARF sequesters Mdm2 in the
nucleolus (37, 45), whereas another observes colocalization of
p19ARF and Mdm2 in nuclear bodies (17). In either setting, p53
is liberated to act unopposed in the nucleoplasm. p19ARF also
interferes with the nuclear export functions of Mdm2, leading
to Mdm2 accumulation in the nucleolus and, in principle,
active p53 in the nucleoplasm (36). In keratinocytes, oncogenic
ras produces a substantial increase in nucleolar and nucleo-
plasmic p19ARF, but Mdm2 does not relocalize to the nucleolus
or to nuclear bodies. Instead, Mdm2 colocalizes with the
fraction of p19ARF that distributes throughout the nucleo-
plasm. Of note, short N-terminal p19ARF peptides inhibit the
Mdm2-mediated ubiquitination of p53 in solution (46, 47), and
perhaps this anti-ubiquitination activity of p19ARF couples Ras
signaling to p53 in keratinocytes. Thus, it appears that p19ARF
can activate p53 through multiple mechanisms.
The responses of primary keratinocytes to oncogenic ras
display remarkable parallels to the progression of chemically
induced skin carcinomas in mice. We show that oncogenic ras
is unable to transform primary keratinocytes, in part, because
it activates a cell-cycle arrest program. Similarly, DMBAy TPA
treatment of murine skin—which produces endogenous ras
mutations—produces benign papillomas that rarely progress
(48). Interestingly, like ras-arrested keratinocytes, these pap-
illomas have elevated levels of wild-type p53 (49). We show
that oncogenic ras induces p19ARF and p53, and that loss of
either protein prevents arrest and facilitates transformation.
Similarly, the progression of chemically induced papillomas to
squamous cell carcinomas is associated with mutations in p53
or at the INK4ayARF locus (8, 26, 50). In addition, p532/2 mice
display a remarkably high rate of malignant conversion of
papillomas to carcinomas, whereas INK4ayARF2/2 and
Fig. 5. ARF-null keratinocytes expressing oncogenic ras form carcinomas in
vivo. Primary keratinocyte cultures derived from wild-type, ARF2/2, and
p532/2 mice were infected with ras-expressing retroviruses or a control vector,
and 5 3 105 cells (per site) were injected s.c. into the rear flanks of athymic
nude mice. (A) Tumor growth was monitored by biweekly caliper measure-
ments of tumor masses at the site of injection. (B) Histological analysis of
tumors derived from ARF2/2 or p532/2 keratinocytes expressing oncogenic ras.
After 3 weeks, tumors were excised from mice and processed for staining with
hematoxylin and eosin. Shown are representative examples at both low and
high magnification. Both tumor types were classified as aggressive and rela-
tively undifferentiated squamous cell carcinomas. All tumors were anaplastic,
with poor cellular organization and without fibrous stroma within the masses.
Most tumors also had multiple areas of necrosis and hemorrhage. White
arrows, mitotic figures; black arrows, keratin pearls.








ARF2/2 mice are prone to skin carcinomas induced by DMBA
and UV irradiation (8, 50). Nevertheless, whereas ras-induced
arrest in vitro occurs over several days, the DMBA-initiated
cells harboring endogenous ras mutations undergo many pop-
ulation doublings before producing a benign papilloma. Per-
haps the MAPK levels produced by ectopic ras expression
exceed those produced by endogenous ras mutations, which
may lead to a more accelerated arrest in vitro. Alternatively,
growth factors in the microenvironment or TPA itself might
delay or attenuate the arrest program. Such additional levels
of regulation are not unprecedented; for example, Rho can
suppress ras-mediated induction of p21, and microenviron-
mental survival factors govern the decision of myc-
overexpressing cells to proliferate or undergo apoptosis (51,
52). In any case, our data provide a provocative explanation for
genetic interactions that promote chemically induced skin
carcinomas. Similar biological and genetic interactions may
occur during the evolution of human carcinomas.
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